Preoperative chemotherapy for stage III-IV gastric carcinoma: feasibility, response and outcome after complete resection - PubMed (original) (raw)
Clinical Trial
. 1995 Sep;82(9):1248-52.
doi: 10.1002/bjs.1800820930.
Affiliations
- PMID: 7552009
- DOI: 10.1002/bjs.1800820930
Clinical Trial
Preoperative chemotherapy for stage III-IV gastric carcinoma: feasibility, response and outcome after complete resection
U Fink et al. Br J Surg. 1995 Sep.
Abstract
Despite extensive resection and systematic lymphadenectomy the prognosis of patients with locally advanced gastric carcinoma remains poor. The effect of preoperative outpatient chemotherapy with etoposide, doxorubicin and cisplatin was evaluated prospectively in 30 patients who had been shown by preoperative staging (including endosonography and surgical laparoscopy) to have gastric carcinoma stages IIIA, IIIB or IV. Haematological side-effects were common and necessitated hospitalization in 13 of 30 patients. Complete clinical response to neoadjuvant therapy was observed in eight of 27 evaluable patients. Resection was performed in 27 of 30 patients, with complete macroscopic and microscopic tumour removal in 24. There were no deaths and no major morbidity following operation. On multivariate analysis complete clinical response (P < 0.01) and complete tumour resection (P < 0.01) were the major independent predictors of long-term survival after neoadjuvant chemotherapy. Actuarial survival after complete tumour removal was superior with neoadjuvant therapy compared with results in an age-, sex- and tumour stage-matched control population who had primary resection (P = 0.07). Recurrence occurred in 17 of 23 evaluable patients who had complete tumour removal, with relapse in the tumour bed or area of lymphatic drainage in 11. These data show that neoadjuvant therapy in patients with locally advanced gastric carcinoma is feasible and appears to increase the rate of complete tumour removal. More powerful and less toxic regimens are, however, required to improve the response rate and to delay or avoid recurrence after neoadjuvant chemotherapy.
Similar articles
- Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up.
Schuhmacher CP, Fink U, Becker K, Busch R, Dittler HJ, Mueller J, Siewert JR. Schuhmacher CP, et al. Cancer. 2001 Mar 1;91(5):918-27. Cancer. 2001. PMID: 11251943 Clinical Trial. - Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma.
Ajani JA, Mayer RJ, Ota DM, Steele GD, Evans D, Roh M, Sugarbaker DJ, Dumas P, Gray C, Vena DA, et al. Ajani JA, et al. J Natl Cancer Inst. 1993 Nov 17;85(22):1839-44. doi: 10.1093/jnci/85.22.1839. J Natl Cancer Inst. 1993. PMID: 8230264 - Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study.
Ott K, Sendler A, Becker K, Dittler HJ, Helmberger H, Busch R, Kollmannsberger C, Siewert JR, Fink U. Ott K, et al. Gastric Cancer. 2003;6(3):159-67. doi: 10.1007/s10120-003-0245-4. Gastric Cancer. 2003. PMID: 14520529 Clinical Trial. - Adjuvant and neoadjuvant therapy for gastric cancer.
Kelsen DP. Kelsen DP. Semin Oncol. 1996 Jun;23(3):379-89. Semin Oncol. 1996. PMID: 8658222 Review. - Etoposide in gastric cancer.
Macdonald JS, Havlin KA. Macdonald JS, et al. Semin Oncol. 1992 Dec;19(6 Suppl 13):59-62. Semin Oncol. 1992. PMID: 1492227 Review.
Cited by
- Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor.
Ott K, Blank S, Becker K, Langer R, Weichert W, Roth W, Sisic L, Stange A, Jäger D, Büchler M, Siewert JR, Lordick F. Ott K, et al. Langenbecks Arch Surg. 2013 Feb;398(2):239-49. doi: 10.1007/s00423-012-1039-0. Epub 2012 Dec 27. Langenbecks Arch Surg. 2013. PMID: 23269519 - Adjuvant and preoperative chemotherapy for gastric cancer.
Yao JC, Ajani JA. Yao JC, et al. Curr Oncol Rep. 2002 May;4(3):222-8. doi: 10.1007/s11912-002-0019-x. Curr Oncol Rep. 2002. PMID: 11937012 Review. - Immediate tumor resection in patients with locally advanced gastroesophageal adenocarcinoma with nonresponse to chemotherapy after 4 weeks of treatment versus resection after completion of chemotherapy (OPTITREAT trial, DRKS00004668): study protocol for a randomized controlled pilot trial.
Blank S, Knebel P, Haag GM, Bruckner T, Klaiber U, Burian M, Schaible A, Sisic L, Schmidt T, Diener MK, Ott K. Blank S, et al. Pilot Feasibility Stud. 2016 Apr 4;2:18. doi: 10.1186/s40814-016-0059-x. eCollection 2016. Pilot Feasibility Stud. 2016. PMID: 27965838 Free PMC article. - Complications of gastrectomy following CPT-11-based neoadjuvant chemotherapy for gastric cancer.
Marcus SG, Cohen D, Lin K, Wong K, Thompson S, Rothberger A, Potmesil M, Hiotis S, Newman E. Marcus SG, et al. J Gastrointest Surg. 2003 Dec;7(8):1015-22; discussion 1023. doi: 10.1016/j.gassur.2003.09.007. J Gastrointest Surg. 2003. PMID: 14675711 - Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954.
Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Van Cutsem E, Siewert JR, Schlag PM. Schuhmacher C, et al. J Clin Oncol. 2010 Dec 10;28(35):5210-8. doi: 10.1200/JCO.2009.26.6114. Epub 2010 Nov 8. J Clin Oncol. 2010. PMID: 21060024 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical